Table 1.
Author, Years | N. of Pts | Type of Lymphoma/Bone Marrow Involvement | Ann Arbor Stage | Response | Other Concomitantly Immunosuppressive Agents |
---|---|---|---|---|---|
Somer, 2003 | 1 | Parotid gland MALT-type/no | IE | Yes | No |
Voulgarelis, 2004* | 4 | IV IIE IV IV |
Yes Yes Yes Yes |
|
|
Harner, 2004 | 1 | Nodal marginal zone/Pulmonary MALT-type/no | IIE | Yes | No |
Ramos-Casals, 2004 | 2 |
|
IV IV |
Yes Yes |
|
Pijpe, 2005 | 1 | Parotid gland MALT-type/no | IE | Yes | No |
Gottenberg, 2005# | 2 | IE IE |
Yes No |
|
|
Pijpe, 2005 | 7 |
|
IE IE IE IE IE IE IE |
No No Yes Yes No Yes No |
|
Voulgarelis, 2006* | 6 | II II IV IIE IV IV |
Yes Yes Yes Yes Yes Yes |
|
|
Seror, 2007# | 5 | IE IV IV IE III |
No Yes Yes Yes Yes |
|
|
Present report | 1 | Parotid gland MALT-type/no | IE | No | High-dose steroids |
There is some patients’ overlapping between the cases reported in Voulgarelis, 2004 and Voulgarelis, 2006.
There is some patients’ overlapping between the cases reported in Gottenberg, 2005 and Seror, 2007.
Abbreviations: pts, patients; MALT, mucosa-associated lymphoid tissue; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; AZA, azathioprine; PDN, prednisone;MTX, methotrexate; MP, methylprednisolone; DLBCL, diffuse large B-cell lymphoma; HQ, hydroxychloroquine.